Peptides vs CBT-I for Insomnia: What Has Actually Been Tested?

For chronic insomnia, CBT-I has much stronger treatment evidence than sleep peptides. Cognitive behavioral therapy for insomnia is designed to improve the difficulty falling asleep, staying asleep, and functioning the next day. Peptide studies often ask a narrower question about hormone release or sleep stages. Those results can be interesting without showing that a peptide treats insomnia.

This comparison examines the trials and official guidance listed below, rather than a personal trial of either treatment. None of these studies directly compares CBT-I with compounded sermorelin or DSIP. We therefore cannot calculate a head-to-head success rate or claim that one produces a particular percentage more benefit. We can explain which research is closer to the problem a person with insomnia wants solved.

Start with the problem you want to treat

“Better sleep” can mean several things: falling asleep sooner, waking less often, feeling rested, or seeing a higher deep-sleep estimate on a watch. These goals are related but not interchangeable. A treatment that changes a laboratory sleep-stage measurement has not necessarily reduced insomnia symptoms. A person can also report worthwhile improvement without a dramatic change in a consumer sleep score.

Write down what is troubling you before comparing programs. Is it time awake in bed, waking much earlier than you want, daytime fatigue, or a device alert? Bring that account to a clinician rather than beginning with the product you hope will solve it. The purpose is to identify an appropriate treatment pathway, not to turn every sleep complaint into a peptide-shopping decision.

Our sleep-peptide overview explains the compounds frequently marketed for this purpose. For interpreting a device result, the sleep-tracker evidence guide separates measurement accuracy from proof that a treatment caused a change.

What CBT-I involves

NHLBI describes CBT-I as a structured treatment, commonly delivered over six to eight weeks, and usually recommended first for long-term insomnia. It can be delivered in person, by telephone, or online. Its components address thoughts about sleep, relaxation, sleep habits, time in bed, and the association between bed and sleep.¹

That is more specific than a list of bedtime tips. When comparing services, ask whether the program delivers a structured CBT-I intervention, what support is available, and how it adapts to your circumstances. A meditation subscription or general wellness coaching should not be assumed equivalent to the interventions studied in CBT-I trials.

Changes to time in bed should be discussed with a qualified professional, particularly if your work involves driving or other activities where sleepiness would create danger. This article does not provide a do-it-yourself sleep-restriction schedule. Treatment needs to fit the person, not just the technique's name.

What the insomnia trials measured

A randomized trial of a digital CBT-I program enrolled 1,711 adults with insomnia complaints and compared it with sleep-hygiene education alongside usual care. It assessed functional health, psychological well-being, sleep-related quality of life, and insomnia outcomes, with benefits reported through the controlled follow-up. Some investigators had commercial relationships with the program developer; that disclosure matters when interpreting the study.²

A separate trial of a web-based intervention followed 303 adults with chronic insomnia. At one year, it reported remission in 56.6% of intervention participants who completed that follow-up (69 of 122); this was not 56.6% of everyone originally randomized. That is a result for that program and trial population, not a guarantee for every online course or person with poor sleep.³

These outcomes are directly relevant to the person asking, “Will I feel and function better?” Their value does not depend on describing CBT-I as perfect. Participation, access, and completing the program still matter. Nor do these studies tell us that every sleep complaint should receive the same intervention without evaluation.

What the peptide sleep studies measured

In a small laboratory study, seven male controls received repeated intravenous GHRH doses or comparison treatments overnight. GHRH increased slow-wave sleep measured with polysomnography.⁴ This is evidence of an acute physiological effect under a particular protocol. It is not a trial of a commercially supplied nightly compounded injection in people seeking treatment for chronic insomnia.

A related study in older adults reported reduced efficacy of GHRH in modifying sleep-endocrine activity.⁵ Age and study conditions therefore deserve attention before a provider presents the first result as a universal promise. Our deep-sleep review explains these studies in more detail.

For a peptide seller's claim, ask which compound, formulation, route, patient group, and outcome match the cited trial. “Peptides affect sleep biology” is a much broader statement than “this prescription reliably treats your insomnia.” Evidence for one member of the group does not establish effectiveness for DSIP, epitalon, or an unspecified blend.

Why a higher hormone number cannot settle the comparison

An IGF-1 result may be relevant to treatment monitoring, but it does not tell you how long you were awake in bed or how well you functioned the following day. Our biomarker guide explains why a treatment's biological activity and its patient benefit must be evaluated separately.

Keep that distinction when reading testimonials. A review that lists a lab change, a wearable score, and a feeling of improvement together may suggest a consistent story, but those are three different observations. They do not become a controlled insomnia trial by being presented in the same paragraph.

Questions to ask before paying for a sleep program

Ask the clinician what diagnosis or working explanation the treatment is intended to address. Then ask how improvement will be measured, what a reasonable review point would be, and what would lead to a different plan. A useful answer names symptoms or outcomes, rather than promising a younger hormone profile.

For CBT-I, ask about the provider's training, program structure, support, cost, and what to do if the exercises are difficult to follow. For a proposed peptide prescription, ask why it is being considered for your situation and what evidence supports that specific use. Also ask who prescribes and which pharmacy would prepare it; our pharmacy verification guide explains the practical checks.

Regulatory wording matters too. An ingredient being discussed for compounding is different from a treatment receiving approval for insomnia. The sleep-peptide regulatory guide explains those distinctions without interpreting a committee discussion as a prescribing endorsement.

When the next step is an evaluation

If the problem has persisted, is affecting your day, or includes symptoms you have not discussed with a clinician, an assessment is more useful than picking between two product advertisements. NHLBI's diagnostic guidance describes history-taking and evaluation for other sleep problems, including sleep apnea where relevant.⁶ A peptide program should not substitute for that assessment.

A productive consultation can be concrete: describe a typical bad night, how often it happens, the next-day effect, your current medicines, and what you have already tried. If you use a tracker, bring the pattern with your own account rather than asking the clinician to diagnose from its stage chart alone. The best starting question is which treatment fits the sleep problem you actually have.